Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration

Selexipag, a selective prostacyclin receptor agonist, is approved for treating pulmonary arterial hypertension in WHO Group 1 adult patients. Compared to parenteral prostacyclin formulations, selexipag offers a significant improvement in patient’s and caregiver’s quality of life because of its oral...

Descripción completa

Detalles Bibliográficos
Autores principales: Faircloth, Jenna M., Bhatt, Neelam D., Chartan, Corey A., Coleman, Ryan D., Villafranco, Natalie, Ruiz, Fadel E., Morales-Demori, Raysa, Whalen, Elise, Ely, Erin, Fombin, Rozmeen, Varghese, Nidhy P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030494/
https://www.ncbi.nlm.nih.gov/pubmed/36969286
http://dx.doi.org/10.3389/fped.2023.1050508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10030494/
https://www.ncbi.nlm.nih.gov/pubmed/36969286
http://dx.doi.org/10.3389/fped.2023.1050508

Ejemplares similares